RxSight - Public Comps and Valuation Multiples

RxSight Overview

About RxSight

RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.

Founded

1997

HQ

Employees

498

Website

rxsight.com

Sectors

Medical Devices
DeepTech
HealthTech

Financials

LTM Revenue $129M

LTM EBITDA -$40.9M

EV

$168M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

RxSight Financials

As of August 2025, RxSight reported last 12-month revenue of $129M and EBITDA of -$40.9M.

In the same period, RxSight generated $93.9M in LTM gross profit and -$44.5M in net income.

See RxSight valuation multiples based on analyst estimates

RxSight P&L

In the most recent fiscal year, RxSight reported revenue of $140M and EBITDA of -$23.8M.

RxSight expects next 12-month revenue of XXX and NTM EBITDA of XXX

See RxSight valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$129M	XXX	$140M	XXX	XXX	XXX
Gross Profit	$93.9M	XXX	$98.9M	XXX	XXX	XXX
Gross Margin	73%	XXX	71%	XXX	XXX	XXX
EBITDA	-$40.9M	XXX	-$23.8M	XXX	XXX	XXX
EBITDA Margin	-32%	XXX	-17%	XXX	XXX	XXX
EBIT	-$52.4M	XXX	-$36.9M	XXX	XXX	XXX
EBIT Margin	-41%	XXX	-26%	XXX	XXX	XXX
Net Profit	-$44.5M	XXX	-$27.5M	XXX	XXX	XXX
Net Margin	-34%	XXX	-20%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for RxSight including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $129M. EBITDA for the last twelve months was -$40.9M. In the most recent fiscal year, RxSight achieved $140M in revenue and -$23.8M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$129M	Analyst estimates available to subscribers	$140M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$93.9M	Analyst estimates available to subscribers	$98.9M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	72.6% gross margin	Analyst estimates available to subscribers	70.7% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	-$40.9M	Analyst estimates available to subscribers	-$23.8M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	-31.6% EBITDA margin	Analyst estimates available to subscribers	-17.0% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	-$52.4M	Analyst estimates available to subscribers	-$36.9M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	-40.5% EBIT margin	Analyst estimates available to subscribers	-26.3% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	-$44.5M	Analyst estimates available to subscribers	-$27.5M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	-34.4% net profit margin	Analyst estimates available to subscribers	-19.6% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for RxSight

This financial data table provides comprehensive performance metrics for RxSight, a company based in United States of America. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

RxSight generated $129M in revenue over the last twelve months.
The company achieved -$40.9M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $93.9M.
Net income over the last twelve months reached -$44.5M.

Fiscal Year Performance

In the most recent fiscal year, RxSight reported $140M in total revenue.
Fiscal year EBITDA was -$23.8M.
The company maintained a gross profit margin of 70.7% in the most recent fiscal year.
EBITDA margin for the fiscal year was -17.0%.
Net profit margin reached -19.6% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for RxSight. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

RxSight Stock Performance

RxSight has current market cap of $384M, and EV of $168M.

Market Cap Evolution

RxSight Stock Data

As of September 30, 2025, RxSight's stock price is $9.

See RxSight trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$168M	$384M	XXX	XXX	XXX	XXX	$-1.09

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

RxSight Valuation Multiples

RxSight's trades at 1.2x EV/Revenue multiple, and -7.1x EV/EBITDA.

See valuation multiples for RxSight and 15K+ public comps

RxSight Financial Valuation Multiples

As of September 30, 2025, RxSight has market cap of $384M and EV of $168M.

Equity research analysts estimate RxSight's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

RxSight has a P/E ratio of -8.6x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$384M	XXX	$384M	XXX	XXX	XXX
EV (current)	$168M	XXX	$168M	XXX	XXX	XXX
EV/Revenue	1.3x	XXX	1.2x	XXX	XXX	XXX
EV/EBITDA	-4.1x	XXX	-7.1x	XXX	XXX	XXX
EV/EBIT	-3.2x	XXX	-4.6x	XXX	XXX	XXX
EV/Gross Profit	1.8x	XXX	n/a	XXX	XXX	XXX
P/E	-8.6x	XXX	-14.0x	XXX	XXX	XXX
EV/FCF	-6.1x	XXX	-7.5x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get RxSight Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

RxSight Margins & Growth Rates

RxSight's last 12 month revenue growth is 2%

RxSight's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.3M for the same period.

RxSight's rule of 40 is -44% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

RxSight's rule of X is -26% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for RxSight and other 15K+ public comps

RxSight Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	2%	XXX	-2%	XXX	XXX	XXX
EBITDA Margin	-32%	XXX	-17%	XXX	XXX	XXX
EBITDA Growth	-2%	XXX	n/a	XXX	XXX	XXX
Rule of 40	-44%	XXX	-15%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	-26%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.3M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.3M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	25%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	97%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial